Novel acyclic halogenated tubercidins (4-amino-5-halo-7-[(2-hydroxyethoxy)-methyl]pyrrolo [2,3-d]pyrimidines) were examined for their ability to inhibit human cytomegalovirus (HCMV) in yield reduction assays. 5-Bromo acyclic tubercidin (compound 102) was a more potent inhibitor of virus replication than the chloro-and iodo-substituted analogs (compounds 100 and 104). At a 100/zM concentration, the bromo and chloro compounds were more potent than acyclovir but not ganciclovir. Virus titers were reduced more than 99% by compounds 102 and 104 whereas compound 100 and the equally potent acyclovir reduced titers by only 90%. Quantitation of viral DNA by DNA hybridization demonstrated strong inhibition of HCMV DNA synthesis by these compounds. The most potent inhibitor, compound 102, had a 50% inhibitory (150) concentration (1.6/tM) comparable to that of ganciclovir (1.8/.tM). Cytotoxicity in uninfected human cells was evaluated and revealed the following: cell growth rates slowed markedly in the presence of 10/zM compound 102 whereas the same concentration of compounds 100 and 104 led to only a slight prolongation of population doubling time; these compounds inhibited cellular DNA synthesis but not RNA or protein synthesis, as measured by incorporation of radiolabeled precursors into acid-precipitable macromolecules; flow cytometry indicated that compound 102 was a mid-S phase blocker, and adenosine antagonized the inhibition of [3H]dThd incorporation by compound 102. Together, these results demonstrate that compound 102 is a potent and selective inhibitor of viral and cellular DNA synthesis and that acyclic halogenated pyrrolopyrimidine nucleosides may have therapeutic potential.
Summary
Novel acyclic halogenated tubercidins (4-amino-5-halo-7-[(2-hydroxyethoxy)-methyl]pyrrolo [2,3-d] pyrimidines) were examined for their ability to inhibit human cytomegalovirus (HCMV) in yield reduction assays. 5-Bromo acyclic tubercidin (compound 102) was a more potent inhibitor of virus replication than the chloro-and iodo-substituted analogs (compounds 100 and 104). At a 100/zM concentration, the bromo and chloro compounds were more potent than acyclovir but not ganciclovir. Virus titers were reduced more than 99% by compounds 102 and 104 whereas compound 100 and the equally potent acyclovir reduced titers by only 90%. Quantitation of viral DNA by DNA hybridization demonstrated strong inhibition of HCMV DNA synthesis by these compounds. The most potent inhibitor, compound 102, had a 50% inhibitory (150) concentration (1.6/tM) comparable to that of ganciclovir (1.8/.tM). Cytotoxicity in uninfected human cells was evaluated and revealed the following: cell growth rates slowed markedly in the presence of 10/zM compound 102 whereas the same concentration of compounds 100 and 104 led to only a slight prolongation of population doubling time; these compounds inhibited cellular DNA synthesis but not RNA or protein synthesis, as measured by incorporation of radiolabeled precursors into acid-precipitable macromolecules; flow cytometry indicated that compound 102 was a mid-S phase blocker, and adenosine antagonized the inhibition of [3H]dThd incorporation by compound 102.
Introduction
Immunosuppressed individuals are susceptible to infection by human cytomegalovirus (HCMV); consequently this opportunistic virus is the causative agent of morbidity and mortality in AIDS patients (Jacobson and Mills, 1988; Klatt and Shibata, 1988; Niedt and Schinella, 1985) and other immunocompromised individuals such as bone marrow transplant recipients and renal allograft patients (Betts and Hanshaw, 1977; Bombi et al., 1987; Glen, 1981) . Neonates also are susceptible to severe HCMV infections (Mostoufi-Zadeh et al., 1984) . Thus, there is an immediate need for non-toxic drugs to treat infections caused by this virus. Although a number of compounds are active against HCMV in vitro (Colacino and Lopez, 1983; Field et al., 1983; Mar et al., 1984; Plotkin et al., 1985) , only the acyclic nucleosides ganciclovir (DHPG) and acyclovir and the pyrophosphate analog foscarnet are sufficiently promising for clinical use against certain HCMV infections (Collaborative DHPG Treatment Study Group, 1986; Jacobson and Mills, 1988; Meyers et al., 1988; Morris, 1988; Rosecan et al., 1986; Shepp et al., 1985; Skolnick and Hirsch, 1988) . Nonetheless, these compounds suffer from disadvantages of low potency (Meyers et al., 1988) , lack of efficacy in certain circumstances (O'Donnell et al., 1987; Shepp et al., 1985) , and cytotoxic manifestations in some therapeutic regimens (Morris, 1988; Skolnik and Hirsch, 1988) . Thus, there is yet a substantial need to discover more potent and safer drugs to treat HCMV infections.
In our search for novel and more efficacious drugs to treat infections caused by herpesviruses, particularly HCMV, we have found that pyrrolopyrimidine nucleosides are potent inhibitors of HCMV in vitro. Particularly, certain deoxyribosyl and arabinosyl pyrrold [2,3-d] pyrimidines have selective antiviral activity against this virus (Turk et al., 1987b) . Of these fraudulent nucleosides, ara-sangivamycin, aratoyocamycin, and 2'-deoxysangivamycin had the best antiviral selectivity. Based upon this lead, our group designed and synthesized acyclic analogs of tubercidin, toyocamycin, and sangivamycin (Gupta et al., 1989a,b; Pudlo et al., 1988 Pudlo et al., , 1990 Saxena et al., 1988) with the objective of reducing cytotoxicity and retaining antiviral activity. Five-halogen substituted analogs of tubercidin have shown particularly good activity against HCMV in early investigations (Pudlo et al., 1988 . In the present work, we have expanded the antiviral assessment of some of these novel halogenated acyclic tubercidin analogs against HCMV and have explored the cellular and molecular basis by which these compounds act.
Materials and Methods

Chemicals
The acyclic tubercidin analogs referred to herein as compounds 080, 100, 102, and 104 were synthesized in the laboratory of one of us (LBT) as described previously Pudlo et al., 1988) . They are, respectively, 4-amino-7-[(2-hydroxyethoxy)methyl]pyrrolo [2,3-d] pyrimidine and its 5-chloro, 5-bromo, and 5-iodo derivatives (Fig. 1) 
Cells and virus
KB cells, an established human cell line derived from an epidermal oral carcinoma, were routinely grown in minimal essential medium (MEM) with Hanks salts [MEM(H)] supplemented with 5% fetal bovine serum. Diploid cell cultures of human foreskin fibroblasts (HFF) were grown in MEM with Earle salts [MEM(E)] supplemented with 10% fetal bovine serum. Cells were passaged by conventional procedures by using 0.05% trypsin and 0.02% EDTA in a HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid)-buffered salt solution [HBS (Shipman, 1969) ]. To increase the likelihood of detecting bacterial or mixed bacterial and mycoplasmal contamination, antibiotics were never used in the routine passage of cells (Hayflick, 1973) . Cell lines were screened periodically and were mycoplasma free.
The plaque-purified isolate (P0) of the Towne strain of HCMV was a gift of Dr. Mark Stinski, University of Iowa. The preparation of HCMV stocks and the titration of virus were performed as described previously (Turk et al., 1987b) .
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Assay for antiviral activity
The effect of the selected compounds on the replication of HCMV was measured using a titer (yield) reduction assay as we reported previously (Turk et al., 1987b) . Briefly, monolayer cultures of HFF cells were infected at a multiplicity of infection of 0.5 PFU per cell and incubated in the presence of test compounds for 7 to 10 days. Following three cycles of freezing at -76°C and thawing at 37°C, the resulting lysates were diluted and the amount of infectious virus was quantitated on new cultures of HFF cells.
Quantification of viral DNA
Viral DNA synthesized in HCMV-infected cells was quantitated by DNA-DNA dot blot hybridization procedures as detailed previously (Turk et al., 1987b) . Briefly, cultures were infected with 0.5 PFU per cell and incubated with test compounds for seven days. Cultures were harvested and filtered through a Gene Screen membrane (New England Nuclear Corp., Boston, MA). The membrane was hybridized with an E. coli plasmid probe (pACYC-184, obtained through the courtesy of Dr. Stinski) containing a fragment of the HCMV genome which had been nick translated with [32p]dCTP. The hybridized label was quantitated using a Beckman model LS 8100 liquid scintillation spectrometer.
Uptake of labeled precursors
Activity of compounds in uninfected KB cells as well as in HFF cells was determined by measuring the effects of compounds on cellular DNA, RNA and protein synthesis essentially as described previously (Turk et al., 1987b; Birch et al., 1989) . Briefly, monolayer cultures were incubated for 18 to 24 h in the presence of test compounds and either [3H]dThd, [3H]Urd, 3H-amino acids, or [32p]Pi at a final concentration of 2 to 3//Ci/ml of labeled precursor.
[3H]dThd and [3H]Urd were diluted with unlabeled nucleoside to give a final concentration of 3 to 6/tM (noninhibitory during the course of the assay). At the end of the incubation period, cells were harvested onto filter paper using a Skatron cell harvester (Skatron, Inc., Sterling, VA) and washed free of unincorporated label with sequential washes of 5% trichloroacetic acid and water. Radioactivity was quantitated using a liquid scintillation spectrometer. Cultures labeled with [32p]Pi were incubated with 1 N NaOH for 2 h at 37°C prior to harvesting to hydrolyze RNA.
Separation of cellular DNA and RNA by isopycnic centrifugation in Cs2S04
The method for Cs2SO4 isopycnic centrifugation was a modification of the procedure described by Stenberg et al. (1988) . [32P]Pi at a final concentration of 3 /.tCi/ml was added to untreated and drug-treated KB cell monolayers to label cellular DNA and RNA. Following an incubation period of 24 h, ceils were harvested by adding 0.25 M EDTA (pH=8.0) and the cell suspensions were centrifuged at 139 low speed for 5 min at 5°C. The resulting pellets were stored at -20°C until further analysis. The pellets were thawed, suspended in 1.2 ml of TES buffer (30 mM Tris, 5 mM EDTA, 50 mM NaC1, pH=8.0) and vortexed. Subsequent isolation of nucleic acids was accomplished by adding 1.2 ml of a solution of pronase (4 mg/ml) in TES buffer containing 2% sarkosyl to the pellet suspension and incubating for 20 min at 37°C. One ml of the resulting suspension was mixed with 9 ml of 1.93 M Cs2SO4 in TES buffer (0.8 g/ml) and centrifuged at 120 000 x g for 66 h at 15°C in a Beckman L3-50 ultracentrifuge using a Ti 70.1 rotor. Samples were collected from the bottom of the centrifuge tubes and 50 fll of each fraction was transferred to a well of a 96-well tissue culture plate. The contents of each well were treated with 5% trichloroacetic acid and then collected onto filter paper using the Skatron cell harvester. The radioactivity of acid-precipitable materials was determined as detailed above.
Cell growth rates
The growth rates of uninfected KB and HFF cells were determined as described by Nassiri et al., 1990 . Population doubling times were calculated using numbers of cells obtained at 24 and 96 h after planting.
Plating efficiency
An additional assay, plating efficiency, was used to confirm and extend results from cell growth experiments. KB and HFF cells were suspended in growth medium and an aliquot containing 500-600 cells was added to a 140 x 25 mm petri dish. Growth medium (40 ml) containing selected concentrations of test compounds was added and the cultures were incubated in a humidified atmosphere of 4% CO2-96% air at 37°(2 for 14 days. Medium was decanted and attached cells were fixed with methanol and stained with 0.1% crystal violet in 20% methanol. Macroscopic colonies >1 mm in diameter were enumerated.
Flow cytometry
Cultures of KB cells as well as HFF cells were incubated with or without compound 102. Cell cycle analysis by flow cytometry was accomplished on a EPICS V flow cytometer (Coulter Electronics, Miami, FL) fitted with an argon-ion laser emitting at 488 nm (400 mW), a 515-nm long pass filter, 560-nm dichroic filter and 630-nm long pass filter. A minimum of 10 000 cells were analyzed for each histogram generated. Details of the methods have been described earlier .
Data analysis
Dose-response relationships were used to compare drug effects. These were constructed by linearly regressing the percent inhibition of parameters derived in the preceding sections against log drug concentrations. The 50% inhibitory 05o) concentrations were calculated from the regression lines using the methods described by Goldstein (1964) . Dose-response relationships for DNA histograms were evaluated by methods described previously (Drach et al., 1981) . Briefly, the total area under the histogram was quantitated and normalized for the number of cells present in each culture.
Results
Activity against HCMV
The antiviral activity of the acyclic halogenated tubercidin analogs previously described by us as compounds 10, 11, and 12, but referred to herein as compounds 100, 102 and 104 ( Fig. 1) , was initially discovered using plaque-reduction assays (Pudlo et al., 1988) . Those results showed the compounds were active against HCMV in the micromolar range 05o = 16, 3.9 and 24/tM, respectively). In order to more completely define activity against HCMV, yield (titer) reduction experiments were employed in the current study. Fig. 2 displays results of such experiments and compares the activities of the three compounds to that of acyclovir, a known antiviral nucleoside with the same acyclic sugar. In agreement with our previous results (Pudlo et al., 1988 ) the acyclic bromotubercidin analog (compound 102) was the most potent of the four agents tested against HCMV. At a concentration of 100 /~M, compound 102 reduced the virus titer well below 1% of control. Compound 104 was approximately 5-fold less potent at this concentration whereas compound 100 and acyclovir were almost 50 times less potent than compound 102. None of the compounds tested, however, was as potent as ganciclovir --another clinically useful antiviral compound possessing a different acyclic sugar. Virus titers were reduced 105-fold by 32 ¢tM ganciclovir (data not shown). 
Effects on labeled precursor incorporation in uninfected cells
When the inhibitory effects of the three acyclic compounds on uninfected cells were measured by visual inspection as part of plaque-reduction assays, compounds 100, 102, and 104 produced virtually no cytopathogenic effects at 100/.tM (Pudlo et al., 1988) . In contrast, when the effects of the compounds were measured by the uptake of labeled precursors, inhibition was noted. Parts B and C of Table 1 32p-labeled RNA and DNA isolated from drug-treated cultures were separated on Cs2SO4 gradients. Fig. 3 shows the Cs2SO4 isopycnic profiles of nucleic acids from untreated KB cells and cells treated with 10 aM of compound 102. As seen from the profiles, the amount of radioactivity incorporated into RNA was equal in both untreated and treated cells, showing no inhibition of RNA synthesis occurred. In contrast, the amount of radioactivity incorporated into DNA in treated cultures suggested nearly a 45% reduction in cellular DNA synthesis. At concentrations of 3.2 and 32 aM of the same compound, 33% and 83% reductions in the synthesis of DNA were noted respectively (profiles not shown). At 32 aM, a 48% reduction in RNA synthesis occurred. Dose-response relationships for the inhibition of DNA synthesis were constructed from the Cs2SO4 gradient profiles and an I50 concentration of 7.2 aM was interpolated. This value is consistent with that obtained by 32p-labeling and hydrolysis (11 aM, Table 1 ) but is inconsistent with that attained by [3H]dThd incorporation (0.38 aM). 
Cell growth and population doubling time
Because DNA histograms showed definite S-phase blockage of DNA synthesis the effects of compounds on suppression of cell growth in uninfected KB and HFF cells were investigated. Growth curves were generated in the presence and absence of test compounds. During a typical 70-h incubation, untreated KB cells underwent three population doublings. Concentrations up to 10/AVI compound 104 and 100 ¢tM compound 100 only slightly increased the doubling time of KB cells to 27-30 h (Table 2) . Compound 102 was significantly more potent. A 10-¢tM concentration of compound 102 caused a pronounced prolongation of cell doubling time to 84 h. The effect of these compounds on HFF cells was slightly less pronounced than their effect on KB cells (data not shown). 
Plating efficiencies
The effects of the acyclic compounds on the attachment and colony formation of KB and HFF cells were determined as a more stringent measure of their effects on uninfected cells. The results of plating efficiency assays are presented in Table 3 as 150 concentrations. Included in the comparison is compound 080 which is the parent compound of the series, unsubstituted in the 5-position. This compound is inactive against HCMV and is non-cytotoxic in other assays (Saxena et al., 1988 ). In the current study it also did not affect the plating and growth of KB cells (Table 3) . In contrast, the halogenated analogs inhibited the capacity of KB cells to attach and form colonies at concentrations similar to those which inhibit [3H]dThd incorporation (see Table 1 ). Surprisingly, ganciclovir was inhibitory in this assay at concentrations 10-fold less than those required to inhibit labeled precursor incorporation (Table 1 ). All compounds, including compound 080 and ganciclovir, had more pronounced effects on HFF cells than KB cells. The marked effect of compound 080 showed that HFF cells are particularly sensitive to the pyrrolopyrimidine nucleosides. This probably is due in part to the lower cloning efficiency of HFF cells compared to KB cells. 
Antagonism of effects on [3H]thymidine incorporation by adenosine
Previous studies by us (Birch et al., 1989) have shown that the effect of sangivamycin [a pyrrolopyrimidine nucleoside phosphorylated by adenosine kinase (Suhadolnik, 1979) ] on [3H]dThd incorporation by uninfected cells is antagonized by adenosine. To explore if effects of the acyclic halogenated tubercidin analogs on [3H]dThd incorporation by KB cells also might be mediated by adenosine kinase, similar studies with compounds 100 and 102 were performed. Dose-response relationships for inhibition of [3H]dThd incorporation by the two compounds were examined at selected concentrations of adenosine. All concentrations of adenosine from 3.2 to 50 pM caused dose-response curves to shift to the right (data not shown). Table 4 presents 150 concentrations from these curves and establishes that the activity of both compounds was antagonized by adenosine. These data suggest that antagonism may have occurred at the kinase level.
Discussion
Our initial testing of acyclic halogenated pyrrolo [2,3-d] pyrimidines showed these compounds were active against HCMV and herpes simplex virus (HSV) type 1 and did not produce visual cytotoxicity in uninfected cells (Pudlo et al., 1988) . Subsequent studies showed, however, that compound 102 inhibited cell growth but did so in a reversible, cytostatic manner. Thus, no visual cytotoxicity was noted earlier (Pudlo et al., 1988) because cell death had not occurred even though cell division was blocked.
The current study was initiated to explore cellular and molecular mechanisms by 146 which compound 102 and two closely related analogs produce antiviral and cytostatic activity, Based upon results presented in this report, the biochemical actions of the acyclic halogenated pyrrolopyrimidines appear to be more restricted than the actions of the parent naturally-occurring nucleosides tubercidin, toyocamycin, and sangivamycin (Suhadolnik, 1979; Ritch and Glazer, 1984) . These ribosyl pyrrolopyrimidines inhibit virus replication but are highly cytotoxic as well (Turk et al., 1987b) . Results with all three acyclic halogenated compounds, but especially results with compound 102, clearly demonstrate inhibition of both cellular and viral DNA synthesis as primary events. Even though Yang et al. (1990) found evidence for inhibition of protein synthesis in guinea pig CMV-infected cells at high concentrations (800 tiM) of compound 102, we found little or no inhibition of RNA or protein synthesis at concentrations (up to 100 ~M) which gave good activity against HCMV. These short-term studies (24 h), however, were not designed to be fully indicative of potential secondary effects accumulating during long-term exposure to the compounds. The questions of whether inhibition of DNA synthesis is sufficient to account entirely for antiviral activity and whether preferential inhibition of viral DNA synthesis occurs are still not fully answered. Data favoring the interpretation that the compounds have antiviral selectivity include the observation that viral DNA synthesis was inhibited by drug concentrations approximately 10-fold lower than required for inhibition of cellular DNA synthesis as measured by [32p]Pi incorporation (Table 1 and Fig. 3 ). In addition, concentrations of compounds 102 and 104 (e.g. 10/AVI) which inhibited HCMV replication by >95% (Fig. 2) produced only slight (compound 104) or 3-fold (compound 102) increases in population doubling times of uninfected cells (Table 2) . Further evidence for viral specificity are data by Hu and Hsiung (1989a) which show a marked multiplicity of infection effect for the activity of compound 102 against guinea pig lymphotropic herpesvirus (GPHLV). Arguing against the theory of antiviral selectivity are data obtained by [3H]dThd incorporation (Table 1) , flow cytometry (Fig. 4) and plating efficiency (Table 3) . Cellular DNA synthesis as measured by these two means and plating efficiency were more sensitive to inhibition by the compounds than was viral DNA synthesis.
Clearly, more investigation is needed to reconcile these disparate results. The lack of agreement of the isotopic methods for quantitating DNA synthesis is particularly puzzling. Previously we had observed a similar phenomenon with ribavirin wherein [3H]dThd incorporation was more sensitive to inhibition than was [32p]Pi incorporation (Drach et al., 1981) . In that case, however, results from flow cytometry correlated better with the [32p]Pi data than the [3H]dThd results. It was discovered that [3H]dThd incorporation greatly overestimated inhibition of DNA synthesis due to drug-induced perturbations in labeled thymidine nucleotide pools. A similar explanation does not appear to apply in the present case and it is difficult to envision a mechanism whereby these compounds could increase the specific activity of the [32p]-labeled dNTP pools and effect an overestimation of inhibition of DNA replication.
Enzymatic mechanisms by which these compounds act have not been explored 147 directly. Our data and that of others do, nonetheless, suggest biochemical bases for the action and possible antiviral selectivity of the compounds. Based on the facts that DNA but not RNA or protein synthesis is inhibited and that related nucleoside analogs such as acyclovir must be phosphorylated to inhibit DNA synthesis (Drach, 1984) , we assume that the acyclic compounds also must be phosphorylated. For the reasons that HCMV does not encode any currently known nucleoside kinases (Kit, 1979) , the activity of compound 102 against HSV type 1 is cell-line dependent (Hu and Hsiung, 1989b ) and the inhibition of [3H]dThd incorporation by uninfected cells is antagonized by adenosine (Table 4) , we speculate that this compound is activated by cellular adenosine kinase. Despite the possibility that HCMV-encoded nucleoside kinases may not exist, it has been demonstrated that cellular nucleoside kinases are stimulated during HCMV infection (Estes and Huang, 1977; Freitos et al., 1985) . This could lead to preferential phosphorylation of the acyclic halogenated tubercidin analogs by virus-infected cells and confer some degree of antiviral specificity. The site of action of putative nucleoside phosphates is even more speculative. Labeled precursor incorporation, DNA-DNA hybridization and flow cytometry data all show inhibition of DNA synthesis. The most logical loci of inhibition are DNA polymerase and ribonucleotide reductase. Indeed, the 5 -triphosphate of the arabinosyl analog of tubercidin is an inhibitor of cellular and HSV-encoded DNA polymerases (Turk et al., 1987a) as well as HCMV-encoded DNA polymerase (our unpublished data). Furthermore, the need to keep compound 102 in contact with cells for it to express antiviral (Yang et al., 1990 ) and cytostatic activity (Nassiri et a1.,1990) plus the fact that these activities are reversed by drug removal, suggest the following: incorporation into DNA and blockage of chain elongation are not likely mechanisms of DNA synthesis inhibition or incorporated molecules are readily removed from DNA by repair mechanisms.
The 5'-diphosphates of tubercidin and toyocamycin have been reported to be substrates (and therefore potential inhibitors) of ribonucleotide reductase derived from E. coli (Chassey and Suhadolnik, 1968) . The accumulation of cells in mid Sphase by compound 102 is similar to results seen when cells are treated with high concentrations of dThd (our unpublished results), a condition wherein reductase is inhibited via feedback regulation by dTTP (Nutter and Cheng, 1984) . In contrast, cells treated with hydroxyurea (a more potent inhibitor of ribonucleotide reductase) accumulate at the G~/S border (Bhuyan and Groppi, 1989) , suggesting that compound 102 is not an exceptionally potent inhibitor of ribonucleotide reductase. Firm data to resolve possibilities such as these await enzymatic studies to more fully understand the mode-of-action of these novel compounds.
